MONISTAT-DERM (miconazole nitrate) by Sight Sciences is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1974.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
MONISTAT-DERM (miconazole nitrate) is a topical antifungal cream that exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. It is indicated for the treatment of vulvovaginal candidiasis and is available as both a 3-day suppository (200 mg) and 7-day cream (2%) formulation. The drug is minimally absorbed systemically, with less than 1% of the administered dose recovered in urine and feces.
Product is in late lifecycle stage with moderate competitive pressure (30%), suggesting team contraction and shift toward defensive positioning.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT-DERM at Sight Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sight Sciences is hiring 2 roles related to this product
Working on MONISTAT-DERM offers limited career growth potential given its late-lifecycle status and zero current job openings. Roles are concentrated in defensive commercial and operational functions rather than innovation, making this an assignment for experienced professionals managing legacy portfolios or early-career professionals seeking OTC market exposure.